|Day Low/High||43.43 / 44.19|
|52 Wk Low/High||37.24 / 45.58|
Which stocks will be most favored by the corporate-bond purchases?
Parents, young adults urged to educate themselves about meningitis B, responsible for one-third of U.S. cases
This market is like a leaky helium balloon; watch out for sudden downdrafts.
Two companies, one a tech giant and the other a Big Pharma stalwart, have formed a joint venture that's bringing disruptive technology to new drug development.
This big pharma blue chip is on a growth trajectory that often eludes companies of its massive size.
The Google parent and Big Pharma major have announced a joint venture into the developing world of bioelectronics treatments.
GlaxoSmithKline's (GSK) Dr. Slaoui believes the company's partnership with Alphabet (GOOGL) will create new nano devices to treat chronic diseases.
The pharmaceutical giant is teaming up with Google's parent with as much as $715 million in joint investments.
GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.
Uber reaches an agreement for its China operations to be acquired by local rival Didi Chuxing; Fed's Dudley says don't rule out rate hike this year; U.S. stock futures rise.
The companies will invest $715 million over seven years to develop miniature implantable devices to help chronic diseases.
CEO Soriot says the company's pipeline is progressing well, and predicts a boost to full-year earnings from a decline in the pound.
TheStreet highlights 3 stocks pushing the health care sector higher today.
The U.K.'s leading drugs group lifts its forecast for the full year and confirms dividend payout plans.
Expect a barrage of key indicators and earnings from companies including Deutsche Bank, LVMH, Diageo and AB InBev.
Purchasing managers' surveys point toward a slowdown in U.K services and manufacturing
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
The pharmaceuticals company, led by CEO Joe Jiminez, had its first full quarter of generic competition for its Gleevec cancer drug.
As a bombed-out pound leaves British assets at a discount, who will be next in the post-Brexit M&A binge?
The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.
Bank of England defies market expectations and keeps rate at 0.5%; expects easing in August.
Shares in the U.K.'s leading pharmaceuticals company have risen about 20% since the June 23 Brexit vote.
Bank of England defies market expectations and keeps rate at 0.5%
UniCredit rises after the bank's chairman says asset sales won't address ECB capital demands, while BASF gains in Frankfurt on talk of the transfer of an agricultural unit to Monsanto.